Nuwellis, Inc. (Nasdaq: NUWE) marks five years of supporting the Pediatric Cardiac Critical Care Consortium (PC4) annual conference, collaborating with leading pediatric cardiac institutions to advance fluid management education and awareness. The company's Aquadex SmartFlow system is utilized across major pediatric cardiac centers for managing f...

Nuwellis (NASDAQ: NUWE), a medical technology company focused on cardiorenal conditions, announced the successful closing of a $6.0 million registered public offering. The offering included 1.9 million shares of common stock and pre-funded warrants, with accompanying Series C and D warrants. The public offering price was $0.30 per share with acco...

Nuwellis, Inc. (Nasdaq: NUWE) announced the successful closing of a public offering raising approximately $6.0 million through the sale of 1,903,338 shares of common stock and pre-funded warrants, along with Series C and D warrants. The offering was priced at $0.30 per share with accompanying warrants. Ladenburg Thalmann & Co. Inc. served as the ...

Nuwellis, Inc. (NUWE) reported Q1 2026 net sales of $2.4 million, up 26% year-over-year, with gross margin improving to 70.1%. The company completed the Rendiatech acquisition, appointed new CFO and board members, and expanded commercial coverage. However, the company posted a net loss of $4.3 million and held only $2.2 million in cash with no de...

Nuwellis (NASDAQ: NUWE) has completed its acquisition of Rendiatech, an Israeli developer of automated kidney function monitoring technology. The acquisition expands Nuwellis' capabilities in fluid management and kidney function monitoring, complementing its existing Aquadex SmartFlow System. The technology enables continuous renal monitoring wit...